Therapeutic options for gastroesophageal cancer are limited, with only two targeted agents approved for the treatment of gastric and GEJ adenocarcinoma (neither agent is approved for the treatment of esophageal cancer). Roche/Genentech/Chugai’s Herceptin is the first-line standard of care for HER2-positive metastatic patients, and Eli Lilly’s Cyramza is approved for use in advanced patients following fluoropyrimidine—and platinum-based therapy. The gastroesophageal cancer market is largely untapped and thus represents a lucrative opportunity for drug developers. The late-phase pipeline is buoyant; the eagerly anticipated emergence of multiple therapies including Keytruda (Merck & Co’s) and Opdivo (Bristol-Myers Squibb/Ono Pharmaceuticals) may soon offer gastroesophageal cancer patients a more optimistic outlook.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.